Although DOT1L is implicated in promoting leukemia development, and EPZ5676 monotherapy has shown promise in MLL-fusion leukemia, its effectiveness relies on the epigenetic repression of MLL target genes and continuous intravenous infusion to maintain therapeutic concentrations [78]. Here, KMT2A is linked to leukemia.